Generation Bio Co. (NASDAQ:GBIO) Director Anthony G. Quinn Buys 125,791 Shares

Generation Bio Co. (NASDAQ:GBIO) Director Anthony G. Quinn bought 125,791 shares of the firm’s stock in a transaction on Friday, January 10th. The shares were bought at an average cost of $0.96 per share, with a total value of $120,759.36. Following the transaction, the director now directly owns 214,286 shares of the company’s stock, valued at approximately $205,714.56. This trade represents a 142.14 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Generation Bio Trading Up 0.9 %

GBIO opened at $0.89 on Thursday. Generation Bio Co. has a 1-year low of $0.75 and a 1-year high of $4.65. The stock has a market capitalization of $59.31 million, a price-to-earnings ratio of -0.41 and a beta of 2.72. The business has a 50 day moving average of $1.33 and a 200-day moving average of $2.12.

Institutional Investors Weigh In On Generation Bio

Hedge funds have recently modified their holdings of the business. State Street Corp boosted its position in shares of Generation Bio by 1.2% in the third quarter. State Street Corp now owns 992,188 shares of the company’s stock valued at $2,451,000 after acquiring an additional 11,669 shares during the period. Baker BROS. Advisors LP boosted its position in shares of Generation Bio by 61.1% in the third quarter. Baker BROS. Advisors LP now owns 1,944,945 shares of the company’s stock valued at $4,804,000 after acquiring an additional 737,988 shares during the period. Barclays PLC boosted its position in shares of Generation Bio by 165.5% in the third quarter. Barclays PLC now owns 76,430 shares of the company’s stock valued at $189,000 after acquiring an additional 47,639 shares during the period. Cubist Systematic Strategies LLC boosted its position in shares of Generation Bio by 91.0% in the second quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock valued at $54,000 after acquiring an additional 9,075 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Generation Bio by 31.2% in the second quarter. Bank of New York Mellon Corp now owns 186,756 shares of the company’s stock valued at $527,000 after acquiring an additional 44,378 shares during the period. 95.22% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Needham & Company LLC decreased their target price on Generation Bio from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Wedbush reaffirmed an “outperform” rating and set a $5.00 target price on shares of Generation Bio in a research report on Thursday, November 7th.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.